Investment

#E3 ligases #Investment #Life sciences #Neurodegenerative disorders #TRIMTECH Therapeutics

Part 1: A day exploring Cambridge’s life science scene

DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with a number of local companies and attended events, the first of which she writes about here: A conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. E3 ligases to expand… Read More

#Business & Investment #Exclusive Content

#Artificial intelligence (AI) #Investment #Life sciences #NVIDIA #Sofinnova Partners #Start-ups

Collaboration to accelerate European life sciences startups

Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has collaborated with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational firepower used… Read More

#Business & Investment #News #Start-up Zone

UK financial markets
#Association of the British Pharmaceutical Industry #Investment #Pharmaceutical industry #Research and development #UK #UK government

UK to lose £11bn in pharma R&D investment

The UK could lose out on £11 ($14.8) billion in pharmaceuticals research and development (R&D) investment by 2033, according to WPI Economics.  In the UK, the Voluntary Scheme or VPAG requires companies to pay the Department of Health and Social Care (DHSC) up to a quarter to a third of… Read More

#Business & Investment #News #Trending News

Great British Pounds, Investment
#BioNTech #Investment #Oncology #UK

BioNTech commits to up to £1 billion investment in the UK

Biopharmaceutical company BioNTech has announced a major investment of up to £1 ($1.3) billion over 10 years in the UK, potentially creating more than 400 new jobs in London and Cambridge.  The latest expansion of BioNTech’s presence in the UK builds on the company’s longstanding, positive strategic relationship and experience… Read More

#Business & Investment #News

Cancer research in laboratory
#Investment #Oncology #Prostate cancer #University of Queensland

$1.25 million support for advanced prostate cancer drug

A $1.25 million investment is driving the development of a new treatment for advanced and therapy-resistant prostate cancer at The University of Queensland.  Based on research by Professor Greg Monteith from UQ’s School of Pharmacy and Pharmaceutical Sciences, the drug (QED-203) is being developed by the Queensland… Read More

#Cancer Research #Editor's Choice #News

Map of Europe
#EFPIA #European Commission #Investment #Pharmaceutical industry #Survey

European pharma CEOs threaten exodus to the US

CEOs of the research-based pharmaceutical industry have issued a stark warning to the European Commission that unless Europe delivers rapid, radical policy change then pharmaceutical research, development and manufacturing is increasingly likely to be directed towards the US.  A survey of European Federation of Pharmaceutical Industries and Associations (EFPIA) member… Read More

#Business & Investment #News #Trending News

Beijing city centre
#AstraZeneca #China #Investment

AZ invests $2.5bn in R&D centre and collaborations in Beijing 

AstraZeneca has announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre, together with further research and manufacturing agreements in China.   This investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development… Read More

#Business & Investment #News

#BioInnovation Institute #Biologics / Biotechnology #Biotech hubs #Drug discovery #Funding #Investment #Life sciences #Market reporting #Start-ups #United States

New podcast: Global epicentres of drug discovery innovation

This is the latest episode of the free DDW narrated podcast, titled “Where are the global epicentres of drug discovery innovation?”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Where are the hottest drug discovery hubs in the… Read More

#News

#Cardiovascular disease #European Innovation Council #Investment #VarmX

VarmX awarded €15m by the European Innovation Council

VarmX has been awarded a follow-on equity investment of €15 million from the European Innovation Council (EIC) Accelerator.   The company is working to develop innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders.  The funds received from the investment will… Read More

#Business & Investment #News

#Business #Financing #Fundraising #Investment

New DDW Highlights podcast: 13 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up at the end of last year focused on drug… Read More

#News

#Business #Financing #Fundraising #Investment

This week in drug discovery (6-10 January) 

News round-up for 6-10 January by DDW Senior Digital Content Editor Diana Spencer. Our news round-up at the end of last year focused on drug discovery investment, so it is positive to see that this has also started strong in 2025, with a number of new acquisitions, research… Read More

#News

#Business #Financing #Fundraising #Investment

Listen now: Last DDW Highlights episode of 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we approach the end of 2024, it’s great to see that… Read More

#News

#Business #Financing #Fundraising #Investment

This week in drug discovery (16-20 December) 

News round-up for 16-20 December by DDW Senior Digital Content Editor Diana Spencer. As we approach the end of 2024, it’s great to see that investment in drug discovery is still going strong, with an impressive $300 million raised by AI-focused company SandboxAQ and another significant financing by… Read More

#News

IgE antibodies
#Antibodies #Bifunctional medicine #Cancer research #Funding #Investment #Ottimo Pharma

Bifunctional medicines to extend the lives of cancer patients

Ottimo Pharma has completed a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets. The round was led… Read More

#Business & Investment #Cancer Research #Editor's Choice #News